Q3 EPS Estimate for PDS Biotechnology Boosted by Analyst

PDS Biotechnology Corporation (NASDAQ:PDSB) – Analysts at HC Wainwright raised their Q3 2026 earnings per share estimates for shares of PDS Biotechnology in a research note issued to investors on Wednesday, August 26th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.11) for the quarter, up from their prior forecast of ($0.12). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for PDS Biotechnology’s current full-year earnings is ($0.47) per share. HC Wainwright also issued estimates for PDS Biotechnology’s Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.46) EPS, FY2027 earnings at ($0.33) EPS and FY2028 earnings at ($0.25) EPS.

Other equities analysts have also issued research reports about the stock. Wall Street Zen raised shares of PDS Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings raised shares of PDS Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 14th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $9.00.

PDS Biotechnology Stock Performance

PDS Biotechnology stock opened at $0.22 on Friday. PDS Biotechnology has a fifty-two week low of $0.20 and a fifty-two week high of $1.55. The firm’s 50 day simple moving average is $0.64 and its 200-day simple moving average is $0.81. The company has a debt-to-equity ratio of 2.73, a current ratio of 0.57 and a quick ratio of 0.57. The company has a market cap of $12.20 million, a P/E ratio of -0.34 and a beta of 1.62.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.05).

Institutional Trading of PDS Biotechnology

A number of hedge funds have recently made changes to their positions in PDSB. Virtu Financial LLC purchased a new position in PDS Biotechnology during the fourth quarter valued at approximately $25,000. Geode Capital Management LLC lifted its position in PDS Biotechnology by 8.0% in the 4th quarter. Geode Capital Management LLC now owns 520,398 shares of the company’s stock worth $401,000 after buying an additional 38,399 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of PDS Biotechnology by 25.0% during the 1st quarter. Renaissance Technologies LLC now owns 220,800 shares of the company’s stock valued at $134,000 after buying an additional 44,100 shares during the period. Marshall Wace LLP purchased a new position in shares of PDS Biotechnology during the 2nd quarter valued at $91,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of PDS Biotechnology in the second quarter worth $60,000. 26.84% of the stock is owned by hedge funds and other institutional investors.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical?stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen?presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS?0101, is designed to treat HPV16?positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV?focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.